Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
viveNK CAR-NK (CD19)
- Development stage
- Preclinical
- Lead developer
- Glycostem
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
viveNK CAR-NK (CD19) is an allogeneic, off-the-shelf chimeric antigen receptor (CAR)-engineered natural killer (NK) cell therapy developed by Glycostem Therapeutics. The therapy is derived from umbilical cord blood CD34+ stem cells and engineered using a lentiviral vector to express a CAR targeting the CD19 antigen. It is designed to treat B-cell malignancies and B-cell-driven autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), by inducing the targeted lysis of CD19-positive B cells. As an allogeneic product, it is manufactured as a cryopreserved therapy that can treat multiple patients from a single cord blood unit, potentially offering safety advantages over CAR-T therapies, including a minimized risk of graft-versus-host disease (GVHD) and cytokine release syndrome.
- Brand names
- viveNK
- Other names
- CD19-CAR-NK cell therapyCD-19-CAR-NK cell therapyCD 19-CAR-NK cell therapyengineered NK cell therapy
02
Targets
Beyond the preview
Go deeper on viveNK CAR-NK (CD19).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on viveNK CAR-NK (CD19).